The combined antitumour effect of a new 5-fluorouracil derivative, BOF-A2, and radiation in vivo

British Journal of Cancer

Volumn 74, Issue SUPPL. XXVII, 1996, Pages

  Murata, R ^a   Shibamoto, Y ^a   Miyauchi, S ^b   Hirohashi, M ^b   Takagi, T ^a   Sasai, K ^a   Oya, N ^a   Hiraoka, M ^a  

^a KYOTO UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

BOF A2; CNDP; EM FU; Radiation; SCCVII mouse tumour

Indexed keywords

EMITEFUR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIATION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; TUMOR GROWTH; ANIMAL; ARTICLE; C3H MOUSE; EXPERIMENTAL NEOPLASM; MULTIMODALITY CANCER THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FLUOROURACIL; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL;

EID: 0029948102     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. BYFIELD, JE, CALABRO-JONES, P, KLISAK, I AND KULHANIAN, F. (1982). Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int. J. Radiat. Oncol. Biol. Phys., 8, 1923-1933.
2. CHAUDHURI, NK, MUKHERJEE, KL AND HEIDELBERGER, C. (1958). Studies on fluorinated pyrimidines VII - the degradative pathway. Biochem. Pharmacol., 1, 328-341.
3. FUJII, S, FUKUSHIMA, M, SHIMAMOTO, Y, OHSHIMO, H, IMAOKA, T AND SHIRASAKA, T. (1989). Antitumor activity of BOF-A2, a new 5-fluorouracil derivative. Jpn. J. Cancer Res., 80, 173-181.
4. HIROHASHI, M, KIDO, M, YAMAMOTO, Y. KOJIMA, Y, JITSUKAWA, K AND FUJII, S. (1993). Synthesis of 5-fluorouracil derivatives containing an inhibitor of 5-fluorouracil degradation. Chem. Pharm. Bull., 41, 1498-1506.
5. KAWAHARA, M, NITANI, H, YOSHIDA, K, FURUSE, K, FUKUOKA, M, KIMURA, I. OHTA, M, TAGUCHI, T, SAITO, T AND KIMURA, K. (1992). Late phase II study of BOF-A2, a new oral 5-fluorouracil derivative in lung cancer. J. Jpn. Soc. Cancer Ther., 27, 484.
6. KINOSHITA, H, TAKAHASHI, N, OGURA, M, SPICER, EJF, SWIGART, JL, DEAN, WP AND BLAIR, M. (1994). Toxicity study of Emitefur, a new antineoplastic agent (I) - Single dose toxicity studies in mice, rats and monkeys-. Jpn. Pharmacol. Ther., 22, 81-86.
7. LOKICH, JJ. (1985). Optimal schedule for 5-fluorouracil chemotherapy. Intermittent bolus or continuous infusion. Am. J. Clin. Oncol. (CCT), 8, 445-448.
8. MAEHARA, Y, NAGAYAMA, S, OKAZAKI, H. NAKAMURA, H, SHIRASAKA, T AND FUJII, S. (1981). Metabolism of 5-fluorouracil in various human normal and tumor tissues. Jpn. J. Cancer Res., 72, 824-827.
9. MATSUI, Y. IZUMI, T AND NITANI, H. (1992). Clinical study of 5-FU concentration in the tissue of patients with primary lung cancer treated by oral BOF-A2. J. Jpn. Soc. Cancer Ther., 27, 565.
10. MIYAUCHI, S, IMAOKA, T, UTSUNOMIYA, T, HAYASHI, K, KUBO, M, KAWAGUCHI, T AND MATSUI, Y. (1994). Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels. Jpn. J. Cancer Res., 85, 665-668.
11. OKAYASU, T. SUGIYAMA, K AND MIYAUCHI, S. (1994). Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues. Jpn. J. Cancer Res., 85, 101-105.
12. SHIBAMOTO, Y, YUKAWA, Y, TSUTSUI, M, TAKAHASHI, M AND ABE, M. (1986). Variation in the hypoxic fraction amoung mouse tumors of different types, sizes, and sites. Jpn. J. Cancer. Res., 77, 908-915.
13. SHIBAMOTO, Y. SASAI, K AND ABE, M. (1987). The radiation response of SCCVII tumor cells in C3H/He mice varies with the radiation conditions. Radiat. Res., 109, 352-354.
14. TATSUMI, K, YAMAUCHI, T, KIYONO, K, KISHI, K, YANAGIHARA, Y, IMAOKA, T. KAWAGUCHI, T AND KUBO, M. (1993). 3-cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. J. Biochem., 114, 912-918.
15. WEINBERG, MJ AND RAUTH, AM. (1987). 5-fluorouracil infusions and fractionated doses of radiation: studies with a murine squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 13, 1691-1699.